1 completed, 1 recruiting, 1 unknown. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 1, Recruiting 1, Unknown 1 |
| Phase 2 | 3 | Completed 1, Recruiting 1, Unknown 1 |
Follow RET-altered Non Small Cell Lung Cancer: new trials by email Literature Review of RET-altered Non Small Cell Lung Cancer trials Research Report on RET-altered Non Small Cell Lung Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of TY-1091 in Patients With Advanced Solid Tumors TY-1091 - RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Unknown | TYK Medicines, Inc | 248 | 2023-04-24 | 2024-01-30 |
| Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities TAS0953/HM06 - RET-altered Non Small Cell Lung Cancer, RET-altered Solid Tumors | Phase 1 / Phase 2 | Recruiting | Taiho Pharmaceutical Co., Ltd. | 244 | 2020-12-16 | 2026-08-19 |
| Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors pralsetinib (BLU-667) - RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Completed | Hoffmann-La Roche | 590 | 2017-03-17 | 2025-05-31 |
Carcinoma, Medullary (2) · Neoplasms (2) · Adenocarcinoma (1) · Adenocarcinoma, Papillary (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Carcinoma, Neuroendocrine (1) · Carcinoma, Non-Small-Cell Lung (1) · Colonic Diseases (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Endocrine Gland Neoplasms (1)
Neoplasms, Ductal, Lobular, and Medullary (2) · Adenocarcinoma (1) · Bronchial Diseases (1) · Carcinoma (1) · Carcinoma, Neuroendocrine (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, Inborn (1) · Multiple Endocrine Neoplasia (1) · Neoplasms by Histologic Type (1) · Neoplasms, Germ Cell and Embryonal (1) · Neoplasms, Glandular and Epithelial (1) · Neoplasms, Multiple Primary (1) · Neoplasms, Nerve Tissue (1) · Neoplastic Syndromes, Hereditary (1) · Neuroectodermal Tumors (1)
pralsetinib (1)
Hoffmann-La Roche (1) · TYK Medicines, Inc (1) · Taiho Pharmaceutical Co., Ltd. (1)
China (2) · South Korea (2) · United States (2) · Australia (1) · Belgium (1) · France (1) · Germany (1) · Hong Kong (1) · Italy (1) · Japan (1) · Netherlands (1) · Singapore (1) · Spain (1) · Taiwan (1) · United Kingdom (1)
PMID 34118197, PMID 34118198, PMID 35715405, PMID 35962206, PMID 37282666, PMID 37916501, PMID 37934000, PMID 38009200, PMID 40639400, PMID 41886723
2016 (1)